Aurobindo Pharma Limited said the US Food and Drug Administration conducted a routine inspection of its wholly owned step-down US subsidiary Lannett Company LLC from 17 to 21 August 2026 that concluded with four observations, while its shares rose over 1% to Rs 1,637.75 on 24 August.

Aurobindo Pharma Ltd. is named among Indian firms facing US President Donald Trump's threatened 100% tariffs on imported generic drugs by 2028, but the article says such US manufacturing investments by the company are commercial decisions to push into higher-margin treatments, not responses to tariff pressure, and that tariffs face obstacles that give Indian makers little reason to panic.

Aurobindo Pharma Limited said the USFDA concluded a routine August 17-21, 2026 inspection at its Telangana peptide API arm AuroPeptides with one observation related to facility and equipment maintenance, not data integrity or related GMP compliance, with corrective action initiated and a formal response to follow, while its Raleigh, North Carolina plant was separately classified as Voluntary Action Indicated.

Aurobindo Pharma said the US FDA conducted a routine inspection at AuroPeptides, its peptide APIs manufacturer in Sangareddy, Telangana from August 17 to 21, 2026 and concluded with one observation relating to facility and equipment maintenance, not pertaining to data integrity or related GMP compliance.